[{"id":"9ff75a13-e0fb-4659-a12b-a20b35ef7bb8","acronym":"FLAMINGO-01","url":"https://clinicaltrials.gov/study/NCT05232916","created_at":"2022-02-10T14:52:54.352Z","updated_at":"2025-02-25T13:40:51.671Z","phase":"Phase 3","brief_title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects","source_id_and_acronym":"NCT05232916 - FLAMINGO-01","lead_sponsor":"Greenwich LifeSciences, Inc.","biomarkers":" HER-2 • HLA-A","pipe":" | ","alterations":" HLA-A*02 positive","tags":["HER-2 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • GLSI-100 • GP2"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"}]